Stanley Laman Group Ltd. Purchases 4,627 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Stanley Laman Group Ltd. lifted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 12.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 42,158 shares of the company’s stock after purchasing an additional 4,627 shares during the quarter. Neurocrine Biosciences accounts for 0.8% of Stanley Laman Group Ltd.’s portfolio, making the stock its 26th largest position. Stanley Laman Group Ltd.’s holdings in Neurocrine Biosciences were worth $5,755,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Golden State Wealth Management LLC bought a new position in shares of Neurocrine Biosciences during the fourth quarter worth $25,000. Brooklyn Investment Group lifted its position in Neurocrine Biosciences by 99.1% in the 4th quarter. Brooklyn Investment Group now owns 231 shares of the company’s stock valued at $32,000 after acquiring an additional 115 shares in the last quarter. Blue Trust Inc. lifted its position in Neurocrine Biosciences by 171.9% in the 3rd quarter. Blue Trust Inc. now owns 348 shares of the company’s stock valued at $40,000 after acquiring an additional 220 shares in the last quarter. R Squared Ltd bought a new stake in Neurocrine Biosciences in the 4th quarter valued at $61,000. Finally, UMB Bank n.a. lifted its position in Neurocrine Biosciences by 211.6% in the 4th quarter. UMB Bank n.a. now owns 455 shares of the company’s stock valued at $62,000 after acquiring an additional 309 shares in the last quarter. 92.59% of the stock is owned by institutional investors.

Neurocrine Biosciences Stock Performance

Shares of NBIX opened at $117.18 on Thursday. The firm has a market cap of $11.86 billion, a P/E ratio of 35.62 and a beta of 0.33. Neurocrine Biosciences, Inc. has a 52 week low of $110.95 and a 52 week high of $157.98. The firm’s 50-day simple moving average is $138.49 and its 200 day simple moving average is $131.02.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings data on Thursday, February 6th. The company reported $1.00 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.45%. As a group, equities analysts forecast that Neurocrine Biosciences, Inc. will post 6.53 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently commented on NBIX shares. Morgan Stanley boosted their price objective on shares of Neurocrine Biosciences from $170.00 to $185.00 and gave the company an “overweight” rating in a research report on Tuesday, February 4th. William Blair reaffirmed an “outperform” rating on shares of Neurocrine Biosciences in a research report on Friday, February 7th. Deutsche Bank Aktiengesellschaft began coverage on shares of Neurocrine Biosciences in a research report on Tuesday. They issued a “hold” rating and a $138.00 price objective on the stock. Royal Bank of Canada cut their price target on shares of Neurocrine Biosciences from $154.00 to $148.00 and set a “sector perform” rating on the stock in a research report on Friday, February 7th. Finally, UBS Group boosted their price target on shares of Neurocrine Biosciences from $162.00 to $176.00 and gave the stock a “buy” rating in a research report on Thursday, January 30th. Five equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, Neurocrine Biosciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $166.90.

Insider Buying and Selling at Neurocrine Biosciences

In related news, CEO Kyle Gano sold 980 shares of the stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $118.39, for a total transaction of $116,022.20. Following the sale, the chief executive officer now owns 137,658 shares in the company, valued at approximately $16,297,330.62. This trade represents a 0.71 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Kevin Charles Gorman sold 146,105 shares of the stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $149.46, for a total transaction of $21,836,853.30. Following the sale, the director now owns 514,596 shares in the company, valued at $76,911,518.16. This represents a 22.11 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 226,647 shares of company stock valued at $33,186,271 in the last quarter. Company insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.